Drug-resistant and multidrug-resistant tubercle bacilli

被引:50
作者
Petrini, B [1 ]
Hoffner, S
机构
[1] Karolinska Inst & Hosp, Dept Clin Microbiol, SE-17176 Stockholm, Sweden
[2] Swedish Inst Infect Dis Control, Stockholm, Sweden
关键词
tuberculosis; M-tuberculosis; drug resistance; multidrug resistance; MDR-TB;
D O I
10.1016/S0924-8579(99)00111-9
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Drug resistant (DR) and multidrug resistant (MDR) tuberculosis (TB) is a consequence of human activity and did not exist before chemotherapeutic drugs were introduced. Monotherapy with various drugs in sequence or other inadequate drug regimens have strongly contributed to the creation of MDR-TB. Such TB strains are mainly prevalent in regions with weak national TB programmes or poor socio-economic environments. Strains may also spread in some communities such as poorly administered prisons. From these and other sources, MDR-TB may spread in the population from which travellers might transfer strains between countries and continents. Therefore an effective surveillance of the resistance pattern of TB bacilli is a demanding task ill all countries. In this review some aspects of epidemiology, diagnosis and mechanisms of DR in TB are discussed. MDR-TB is an important international problem of increasing significance for the whole global community. (C) 1999 Elsevier Science B.V. and International Society of Chemotherapy. All rights reserved.
引用
收藏
页码:93 / 97
页数:5
相关论文
共 18 条
[1]  
*AM THOR SOC, 1993, MMWR MORB MORT WKLY, V42, P1
[2]   Origin and interstate spread of a New York City multidrug-resistant Mycobacterium tuberculosis clone family [J].
Bifani, PJ ;
Plikaytis, BB ;
Kapur, V ;
Stockbauer, K ;
Pan, X ;
Lutfey, ML ;
Moghazeh, SL ;
Eisner, W ;
Daniel, TM ;
Kaplan, MH ;
Crawford, JT ;
Musser, JM ;
Kreiswirth, BN .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 275 (06) :452-457
[3]  
COHN DL, 1997, CLIN INFECT DIS S1, V24, P121
[4]  
COLE ST, 1995, EUR RESP J S20, V8, P701
[5]  
Cynamon Michael H., 1994, Clinical Microbiology Newsletter, V16, P20, DOI 10.1016/0196-4399(94)90047-7
[6]   SUSCEPTIBILITY OF STREPTOMYCIN-RESISTANT MYCOBACTERIUM-TUBERCULOSIS STRAINS TO AMIKACIN [J].
HOFFNER, SE ;
KALLENIUS, G .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1988, 7 (02) :188-190
[7]  
Inderlied Clark B., 1995, P1385
[8]  
Laszlo A, 1997, INT J TUBERC LUNG D, V1, P231
[9]   Independent origin of mono-rifampin-resistant Mycobacterium tuberculosis in patients with AIDS [J].
Lutfey, M ;
DellaLatta, P ;
Kapur, V ;
Palumbo, LA ;
Gurner, D ;
Stotzky, G ;
Brudney, K ;
Dobkin, J ;
Moss, A ;
Musser, JM ;
Kreiswirth, BN .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1996, 153 (02) :837-840
[10]   BIOGENESIS OF THE MYCOBACTERIAL CELL-WALL AND THE SITE OF ACTION OF ETHAMBUTOL [J].
MIKUSOVA, K ;
SLAYDEN, RA ;
BESRA, GS ;
BRENNAN, PJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (11) :2484-2489